New Clinic to test

this is a clinic to test There has been longstanding advice regarding avoiding valproate in women of child-bearing potential due to teratogenic risk, however a retrospective observational study looking at electronic medical records in three European Nordic countries has indicated an increased risk of neurodevelopmental disorders (NDDs) in children (aged 0 to 11 years) born to men treated with valproate in the 3 months before conception, compared with those treatment with lamotrigine or levetiracetam. 12
The Product Information (PI) for various brands of valproate have been updated to include precautionary information about the increased risk of NDDs in children born to men treated with valproate during the time of conception.